Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis)
Abstract Introduction Guselkumab is a monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, approved for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis (PsA). While patients with psoriasis often achieve high clinical response rates (Psoriasis Area and Se...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-07-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-025-01476-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849388188352643072 |
|---|---|
| author | Mario Valenti Luciano Ibba Sara Di Giulio Paolo Dapavo Piergiorgio Malagoli Angelo V. Marzano Francesco Loconsole Martina Burlando Anna Balato Valentina Dini Matteo Megna Giampiero Girolomoni Emanuele Trovato Claudia Lasagni Massimo Travaglini Claudio Guarneri Nicola Zerbinati Simone Ribero Francesca M. Gaiani Carlo G. Carrera Emanuele C. Cozzani Eugenia V. Di Brizzi Alessandra Michelucci Luca Potestio Martina Maurelli Martina Dragotto Luca Mastorino Eleonora Bongiovanni Francesco Messina Andrea Sechi Rossana Moroni Antonio Costanzo Alessandra Narcisi |
| author_facet | Mario Valenti Luciano Ibba Sara Di Giulio Paolo Dapavo Piergiorgio Malagoli Angelo V. Marzano Francesco Loconsole Martina Burlando Anna Balato Valentina Dini Matteo Megna Giampiero Girolomoni Emanuele Trovato Claudia Lasagni Massimo Travaglini Claudio Guarneri Nicola Zerbinati Simone Ribero Francesca M. Gaiani Carlo G. Carrera Emanuele C. Cozzani Eugenia V. Di Brizzi Alessandra Michelucci Luca Potestio Martina Maurelli Martina Dragotto Luca Mastorino Eleonora Bongiovanni Francesco Messina Andrea Sechi Rossana Moroni Antonio Costanzo Alessandra Narcisi |
| author_sort | Mario Valenti |
| collection | DOAJ |
| description | Abstract Introduction Guselkumab is a monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, approved for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis (PsA). While patients with psoriasis often achieve high clinical response rates (Psoriasis Area and Severity Index [PASI] 90 and PASI 100), the presence of PsA may influence long-term outcomes. We conducted a 260-week, multicenter, retrospective study to compare the effectiveness, safety, and drug survival of guselkumab in patients with and without concomitant PsA. Methods A total of 1765 patients were enrolled, including 352 with a concomitant diagnosis of PsA and 1413 with isolated skin involvement. All patients were treated with guselkumab following the approved dosing schedule for moderate-to-severe plaque psoriasis for at least 1 year. Treatment effectiveness was evaluated in terms of PASI 90, PASI 100, and absolute PASI ≤ 2 at weeks 16, 28, 52, 104, 156, 204, and 260. Guselkumab drug survival was assessed using the Kaplan–Meier method at the same time points. The safety profile was evaluated by analyzing adverse events recorded in medical charts at each follow-up visit. Results Throughout the study period, response rates remained comparable between the two cohorts of patients, with a significant difference at 2 years of follow-up in terms of PASI 90 (80.51% versus 74.02%). Drug survival overall remained stable and similar, with 79.5% (95% confidence interval (CI) 76.9–81.9) of patients without PsA and 78.5% (95% CI 72.9–83.1) of patients with PsA still receiving guselkumab treatment after 5 years. Conclusions Our results confirm the long-term effectiveness, persistence, and favorable safety profile of guselkumab in patients with moderate-to-severe psoriasis, regardless of the presence of concomitant PsA. |
| format | Article |
| id | doaj-art-eb7652dace8a4b90b8510a2722c77f86 |
| institution | Kabale University |
| issn | 2193-8210 2190-9172 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj-art-eb7652dace8a4b90b8510a2722c77f862025-08-20T03:42:23ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722025-07-011592423243710.1007/s13555-025-01476-1Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis)Mario Valenti0Luciano Ibba1Sara Di Giulio2Paolo Dapavo3Piergiorgio Malagoli4Angelo V. Marzano5Francesco Loconsole6Martina Burlando7Anna Balato8Valentina Dini9Matteo Megna10Giampiero Girolomoni11Emanuele Trovato12Claudia Lasagni13Massimo Travaglini14Claudio Guarneri15Nicola Zerbinati16Simone Ribero17Francesca M. Gaiani18Carlo G. Carrera19Emanuele C. Cozzani20Eugenia V. Di Brizzi21Alessandra Michelucci22Luca Potestio23Martina Maurelli24Martina Dragotto25Luca Mastorino26Eleonora Bongiovanni27Francesco Messina28Andrea Sechi29Rossana MoroniAntonio Costanzo30Alessandra Narcisi31Dermatology Unit, IRCCS Humanitas Research HospitalDermatology Unit, IRCCS Humanitas Research HospitalDermatology Unit, IRCCS Humanitas Research HospitalDermatologic Clinic, Department of Clinical Medicine, University of TurinDepartment of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato MilaneseDermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore PoliclinicoDepartment of Dermatology, University of BariDepartment of Dermatology, Dipartimento di Scienze della Salute (DISSal), University of Genoa, IRCCS Ospedale Policlinico San MartinoDermatology Unit, University of Campania L. VanvitelliDepartment of Dermatology, University of PisaSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico IIDepartment of Medicine, Section of Dermatology, University of VeronaUnit of Dermatology, Department of Medical, Surgical and Neurological Sciences, University of SienaDermatological Clinic, Department of Specialized Medicine, University of ModenaU.O.S.D. Dermatologica-Centro per la Cura della PsoriasiDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging, University of MessinaDermatology Unit, Department of Medicine and Surgery, University of InsubriaDermatologic Clinic, Department of Clinical Medicine, University of TurinDepartment of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato MilaneseDermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore PoliclinicoDepartment of Dermatology, Dipartimento di Scienze della Salute (DISSal), University of Genoa, IRCCS Ospedale Policlinico San MartinoDepartment of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato MilaneseDepartment of Dermatology, University of PisaSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico IIDepartment of Medicine, Section of Dermatology, University of VeronaUnit of Dermatology, Department of Medical, Surgical and Neurological Sciences, University of SienaDermatologic Clinic, Department of Clinical Medicine, University of TurinDermatologic Clinic, Department of Clinical Medicine, University of TurinDepartment of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato MilaneseDermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore PoliclinicoDermatology Unit, IRCCS Humanitas Research HospitalDermatology Unit, IRCCS Humanitas Research HospitalAbstract Introduction Guselkumab is a monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, approved for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis (PsA). While patients with psoriasis often achieve high clinical response rates (Psoriasis Area and Severity Index [PASI] 90 and PASI 100), the presence of PsA may influence long-term outcomes. We conducted a 260-week, multicenter, retrospective study to compare the effectiveness, safety, and drug survival of guselkumab in patients with and without concomitant PsA. Methods A total of 1765 patients were enrolled, including 352 with a concomitant diagnosis of PsA and 1413 with isolated skin involvement. All patients were treated with guselkumab following the approved dosing schedule for moderate-to-severe plaque psoriasis for at least 1 year. Treatment effectiveness was evaluated in terms of PASI 90, PASI 100, and absolute PASI ≤ 2 at weeks 16, 28, 52, 104, 156, 204, and 260. Guselkumab drug survival was assessed using the Kaplan–Meier method at the same time points. The safety profile was evaluated by analyzing adverse events recorded in medical charts at each follow-up visit. Results Throughout the study period, response rates remained comparable between the two cohorts of patients, with a significant difference at 2 years of follow-up in terms of PASI 90 (80.51% versus 74.02%). Drug survival overall remained stable and similar, with 79.5% (95% confidence interval (CI) 76.9–81.9) of patients without PsA and 78.5% (95% CI 72.9–83.1) of patients with PsA still receiving guselkumab treatment after 5 years. Conclusions Our results confirm the long-term effectiveness, persistence, and favorable safety profile of guselkumab in patients with moderate-to-severe psoriasis, regardless of the presence of concomitant PsA.https://doi.org/10.1007/s13555-025-01476-1Anti-IL-23BiologicsPsoriasisPsoriatic arthritisReal-lifeGuselkumab |
| spellingShingle | Mario Valenti Luciano Ibba Sara Di Giulio Paolo Dapavo Piergiorgio Malagoli Angelo V. Marzano Francesco Loconsole Martina Burlando Anna Balato Valentina Dini Matteo Megna Giampiero Girolomoni Emanuele Trovato Claudia Lasagni Massimo Travaglini Claudio Guarneri Nicola Zerbinati Simone Ribero Francesca M. Gaiani Carlo G. Carrera Emanuele C. Cozzani Eugenia V. Di Brizzi Alessandra Michelucci Luca Potestio Martina Maurelli Martina Dragotto Luca Mastorino Eleonora Bongiovanni Francesco Messina Andrea Sechi Rossana Moroni Antonio Costanzo Alessandra Narcisi Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis) Dermatology and Therapy Anti-IL-23 Biologics Psoriasis Psoriatic arthritis Real-life Guselkumab |
| title | Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis) |
| title_full | Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis) |
| title_fullStr | Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis) |
| title_full_unstemmed | Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis) |
| title_short | Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis) |
| title_sort | guselkumab retention effectiveness and safety in psoriasis a 260 week real world multicenter retrospective study exploring the role of concomitant psa il pso italian landscape psoriasis |
| topic | Anti-IL-23 Biologics Psoriasis Psoriatic arthritis Real-life Guselkumab |
| url | https://doi.org/10.1007/s13555-025-01476-1 |
| work_keys_str_mv | AT mariovalenti guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT lucianoibba guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT saradigiulio guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT paolodapavo guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT piergiorgiomalagoli guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT angelovmarzano guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT francescoloconsole guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT martinaburlando guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT annabalato guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT valentinadini guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT matteomegna guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT giampierogirolomoni guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT emanueletrovato guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT claudialasagni guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT massimotravaglini guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT claudioguarneri guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT nicolazerbinati guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT simoneribero guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT francescamgaiani guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT carlogcarrera guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT emanueleccozzani guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT eugeniavdibrizzi guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT alessandramichelucci guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT lucapotestio guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT martinamaurelli guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT martinadragotto guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT lucamastorino guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT eleonorabongiovanni guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT francescomessina guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT andreasechi guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT rossanamoroni guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT antoniocostanzo guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis AT alessandranarcisi guselkumabretentioneffectivenessandsafetyinpsoriasisa260weekrealworldmulticenterretrospectivestudyexploringtheroleofconcomitantpsailpsoitalianlandscapepsoriasis |